Navigation Links
Hospira Launches Generic Irinotecan Injection
Date:2/27/2008

- Offers Unique Formulation of Important Cancer Medication -

LAKE FOREST, Ill., Feb. 27 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced the launch of irinotecan hydrochloride injection in the United States. The medication is a generic version of Pfizer's Camptosar(R), which posted 2007 U.S. sales of more than $545 million. Irinotecan hydrochloride injection is used for patients with colon or rectal cancer whose disease has recurred or progressed following therapy with other treatments.

"We are continuing to grow our leading portfolio of generic medications used to treat patients with cancer," said Robert Felicelli, vice president and general manager, Specialty Pharmaceuticals, Hospira. "By providing irinotecan and other high-quality, lower-cost alternatives to proprietary medications, Hospira is meeting patient needs in this fast-growing therapeutic area."

Hospira's irinotecan product portfolio extends beyond the formulations available from the innovator. In addition to offering the medication in 40 mg and 100 mg single-dose vials, Hospira is also marketing a 500 mg single-dose vial, for additional convenience when preparing and delivering larger doses. The company packages irinotecan in its proprietary Onco-Tain(TM) vials for safe handling.

Hospira offers the broadest generic injectable product portfolio in the world, with more than 190 generic injectable products in more than 900 dosages and formulations. Product areas include cardiovascular, anesthesia, anti-infectives, oncology, analgesics, emergency and other therapeutic segments. A host of proprietary non-biologic drugs are facing patent expiration globally over the coming years, and many of these compounds are in Hospira's robust product pipeline. To help reduce medication errors, Hospira labels all of its injectable products with unit-of-use bar codes.

Hospira already markets irinotecan in Canada, Australia and several European countries.

Indications and Safety Information

Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Common adverse events include diarrhea (early and late), neutropenia, leukopenia, anemia, thrombocytopenia, nausea, vomiting, abdominal cramping, cholinergic symptoms, dizziness, visual disturbances, alopecia, mucositis, pain, weakness and fever.

Boxed Warning: Irinotecan HCl Injection should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. Irinotecan HCl Injection can induce both early and late forms of diarrhea that appear to be mediated by different mechanisms. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion of Irinotecan HCl Injection may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Early diarrhea and other cholinergic symptoms may be prevented or ameliorated by atropine (see PRECAUTIONS, General). Late diarrhea (generally occurring more than 24 hours after administration of Irinotecan HCl Injection) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea should be treated promptly with loperamide. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia (see WARNINGS). Administration of Irinotecan HCl Injection should be interrupted and subsequent doses reduced if severe diarrhea occurs (see DOSAGE AND ADMINISTRATION). Severe myelosuppression may occur (see WARNINGS).

For full prescribing information, including safety and warning information, contact Hospira Medical Information at (800) 615-0187.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.
Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products and biosimilars. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may cause actual results to be materially different from expectations include risks and uncertainties relating to the ability to develop, obtain regulatory approval for, and market and sell generic specialty injectable and biosimilar products; and the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's Annual Report on Form 10-K for the year ended Dec. 31, 2006, and subsequent Quarterly Reports on Form 10-Q, filed with the Securities and Exchange Commission. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
2. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
3. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
4. Hospira Reports Third-Quarter 2007 Results
5. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
6. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
7. eDiets(R) Launches Fresh Meal Delivery Program for alli(R) Users
8. AthletixNation.com Launches Sports Website and Community Programs
9. ARJO, Inc. Launches Two Innovative Products and New Campaign
10. Specialty European Pharma launches plenaxis in Germany
11. GO3 Launches Line of Health-Focused Products with Partner David Beckham
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
Breaking Medicine Technology: